Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial ribosomal 50S subunit in Clostridioides difficile is the larger component of the prokaryotic 70S ribosome, playing a central role in protein biosynthesis (Wilson, 2014). It is composed of 23S ribosomal RNA (rRNA), 5S rRNA, and approximately 33 ribosomal proteins that coordinate the peptidyl transferase reaction (UniProt, 2023). This subunit serves as the primary binding site for several classes of antibiotics, including macrolides, lincosamides, and oxazolidinones, which inhibit translation by blocking the exit tunnel or the peptidyl transferase center (StatPearls, 2023). In C. difficile, the 50S subunit is a target for drugs like linezolid and the investigational antibiotic cadazolid, which aim to halt the production of essential proteins and toxins (Chilton et al., 2014). However, the use of broad-spectrum 50S inhibitors can lead to significant gut dysbiosis, which is a primary driver for the overgrowth of C. difficile and subsequent infection (PubMed, 2022). Resistance to these treatments often arises through the methylation of the 23S rRNA by Erm methyltransferases, preventing drug binding (Nature Reviews Microbiology, 2014). Consequently, the 50S subunit is a focal point for both the treatment of C. difficile and the unintended induction of the disease by other antibiotics. Research into the specific structure of the C. difficile 50S subunit continues to inform the design of more selective antimicrobial agents.
Inhibition of bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, which blocks the peptidyl transferase center or the ribosomal exit tunnel, thereby preventing peptide bond formation or nascent chain elongation (Wilson, 2014).
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial ribosomal 50S subunit (Clostridioides difficile) (50S subunit).